Patents Assigned to SHANGRAO CONCORD PHARMACEUTICAL CO., LTD.
  • Patent number: 11919936
    Abstract: Provided are a TEV protease variant, a fusion protein thereof, a preparation method therefor and the use thereof. Provided are a TEV protease variant with unique properties obtained by screening and a fusion protein thereof. The TEV protease variant has a low enzyme cleavage activity during expression in hosts, and preferably has a lower enzyme cleavage activity compared to an S219V variant having an amino acid sequence as shown in SEQ ID NO: 10. The enzyme cleavage site of the TEV protease variant is selected from EXXYXQG/S/H, wherein X is any amino acid residue, and the enzyme cleavage site is preferably selected from SEQ ID NO: 7 and 8. Fusion expression using the TEV protease variant of the present invention and a polypeptide can be used for preparing a polypeptide quickly and efficiently, thereby solving the problems currently present in the process of the recombinant production of a polypeptide.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 5, 2024
    Assignee: SHANGRAO CONCORD PHARMACEUTICAL CO., LTD.
    Inventors: Rikui Liu, Xiaolong Zou, Jianghua Wan